Seminar Crohn's disease
Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract with increasing incidence worldwide. Crohn's disease might result from a complex interplay between genetic susceptibility...
View ArticleAbbVies risankizumab bags Orphan status for paediatric Crohns
An experimental therapy being developed by AbbVie for paediatric patients with Crohn's disease has been awarded Orphan Drug status in the US.
View ArticleAbbVies risankizumab secures FDA orphan drug status for paediatric Crohns
AbbVie has secured Orphan Drug Designation from the US Food and Drug Administration FDA to risankizumab ABBV066; formerly BI 655066 for the investigational treatment of Crohn's disease in pediatric...
View ArticleGlobal Gastrointestinal Therapeutics Market 20162020 Prices from USD $2500
About Gastrointestinal DisordersGastrointestinal disorders include both functional and motility disorders affecting the gastrointestinal tract. Functional disorders involve an abnormality in the...
View ArticleStelara Ustekinumab for the Treatment of Moderate to Severe Crohns Disease
Developed by Janssen Biotech Stelara Ustekinumab is indicated for the treatment of moderate to severely active Crohn's disease.
View ArticleFDA grants orphan status to AbbVie's risankizumab
AbbVie has received an orphan drug designation from the FDA for ABBV066 or risankizumab for treatment of Crohn's disease i More
View ArticleMaxor Completes Its Acquisition of Pharmaceutical Specialties Inc. PSI
AMARILLO Texas Dec. 2 2016 PRNewswire Maxor National Pharmacy Services LLC "Maxor" today announced that it has completed its acquisition of Pharmaceutical Specialties Inc. "PSI". The combination of...
View ArticleAbbVies Risankizumab Receives Orphan Drug Designation for Treatment of...
NORTH CHICAGO Ill. Nov. 30 2016 PRNewswire &8212;ÂAbbVie NYSE ABBV a global biopharmaceutical company today announced that the U.S. Food and Drug Administration FDA has granted Orphan Drug...
View ArticleEU Crohn's and Colitis Org Reverses View on Biosimilar Use
NewsNew statement from European Crohn's and Colitis Organization supports switching to biosimilar from reference product in inflammatory bowel disease.
View ArticleRedHill Biopharma Announces Phase IIa 48Week Final Results Further Supporting...
Thought to be autoimmune in nature the multiple sclerosis MS inflammatory process is also consistent withÂan infectious disease; The CEASEMS Phase IIa proofofconcept PoC singlearm openlabel study was...
View ArticleGEMINI II & III Posthoc Analysis Reports Clinical Benefits of Vedolizumab as...
Osaka Japan December 9 2016 Takeda Pharmaceutical Company Limited TSE 4502 “Takeda” announced that an analysis based on prespecified and posthoc exploratory outcomes of GEMINI II...
View ArticleSoligenix Inc. Prices $5277000 Public Offering and Completes Listing on Nasdaq
PRINCETON N.J. Dec. 13 2016 PRNewswire Soligenix Inc. Nasdaq SNGX a latestage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
View ArticleBRIEFRedhill Biopharma says positive DSMB recommendation for continuation of...
Redhill Biopharma announces positive and unanimous DSMBrecommendation for continuation of Phase III study with RHB104for Crohn's disease
View ArticleArena Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare...
SAN DIEGO Dec. 13 2016 PRNewswire Arena Pharmaceuticals Inc. NASDAQ ARNA today announced that Amit Munshi the Company's President and Chief Executive Officer will present a corporate update at the 35th...
View ArticleRedHill Biopharma Ltd. RedHill Biopharma Announces Positive and Unanimous...
Following a preplanned review of safety data RedHill has received a unanimous recommendation from the independent Data and Safety Monitoring Board DSMB to continue the MAP US Phase III study...
View ArticleRedHill Biopharma Announces Positive and Unanimous DSMB Recommendation for...
Following a preplanned review of safety data RedHill has received a unanimous recommendation from the independent Data and Safety Monitoring Board DSMB to continue the MAP US Phase III study with...
View ArticleJanssen Release Health Canada Approves STELARA For The Treatment Of Adults...
Life Sciences Jobs ...
View ArticleIntelGenx and RedHill Biopharma Announce Definitive Agreement for...
SAINTLAURENT CANADA Marketwired 121416 IntelGenx Corp. TSX VENTURE IGXOTCQX IGXT and RedHill Biopharma Ltd. NASDAQ RDHLTASE RDHL today announced the signing of an exclusive license agreement with...
View ArticleTillotts Pharma AG's Parent Company Zeria Pharmaceutical Co. Ltd. Launches...
Life Sciences Jobs ...
View ArticleTillotts Pharma AG's Parent Company Zeria Pharmaceutical Launches ZentacortÂ...
RHEINFELDEN Switzerland December 14 2016 PRNewswire Zeria Pharmaceutical Co. Ltd launched Zentacort 3mg capsules generic name Budesonide in Japan on November 29 2016. Zentacort is sold as Entocort in...
View Article